News
Hosted on MSN1mon
Sanofi to Buy Blueprint Medicines for Up to $9.5 Billion in Boost to Pipeline - MSNSanofi agreed to buy Blueprint Medicines for up to $9.5 billion, the French drugmaker’s biggest move yet to replenish its drug pipeline since it sold a controlling stake in its consumer ...
Hosted on MSN26d
Sanofi to Acquire Blueprint Medicines for $9.1 Billion - MSNSanofi has agreed to acquire Blueprint Medicines for $9.1 billion, expanding its footprint in rare immunological diseases. The purchase includes a 27% premium per share and could total nearly $9.5 ...
Sanofi and Blueprint Medicines, a U.S.-based, publicly traded biopharmaceutical company specializing in systemic mastocytosis, a rare immunological disease, and other KIT-driven diseases, ...
From new industry M&As to insights on how to recruit Gen Z talent, there’s plenty to discover in our latest pharma news round ...
Sanofi acquires Blueprint Medicines for $9.1 billion, gaining Ayvakit, a rare disease treatment approved in the US and EU for multiple conditions.
Sanofi announced that it will buy pharma company Blueprint Medicines for $129 per share, making the deal worth more than $9 billion. Blueprint specializes in systemic mastocytosis and other ...
Learn about June 2025’s top biotech deals, featuring major collaborations in small molecules, protein therapeutics, and ...
BIO was as busy as ever in Boston this year. With more to come soon, here are a few initial thoughts on three events I ...
During a talk at the recent Jefferies Global Healthcare Conference, Cogent CEO Andy Robbins said Blueprint Medicines’ Ayvakit was so toxic that it was killing patients. Only after Blueprint lowered ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results